cognitive decline of diabetes mellitus
Conditions
Interventions
Case series:Nil
Sponsors
Affiliated ZhongDa Hospital of Southeast University
Eligibility
Sex/Gender
All
Age
50 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Diabetes diagnosis was formulated in line with WHO 1999 criteria, and a clear diagnosis of type 2; 2. Aged between 50 to 75 years; 3. Complained of memory loss, and confirmed by others; 4. Clinical dementia rating,CDR 0.5; 5. Sufficient visual and auditory resolution to accept neuropsychological tests; 6. No evidence of infection, or other focal infarct damage 12 months prior to the test head CT or MRI scans, and no associated clinical symptoms, but allow a non-critical brain regions without lacunar infarction is thought to affect the test the cognitive impairment; 7. Hachinski ischemia scale(HIS) less than 4.
Exclusion criteria
Exclusion criteria: 1. Acute complications such as diabetic ketoacidosis within the past three months; severe heart, lung, kidney failure history; cerebrovascular accident; 2. Any neurological disease caused by dementia; 3. Suffered from depression in past two years, or Hamilton depression scale score> 10 points; 4. Other disorders which possible cause organic brain dysfunction and mental illness; 5. Application of psychotropic drugs in recent three months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| AGEs;sRAGE;BDNF;Polymorphsm of RAGE Gly82Ser;Polymorphsm of BDNF Val66Met;ACE; | — |
Secondary
| Measure | Time frame |
|---|---|
| mild cognitive impairment;BMI;uric acid;insulin;c peptide;insulin like growth factor-1;GSK3 beta;Abeta 40;Abeta 42;Insulin Degrading Enzyme;cholesteryl ester transfer protein;ATP-binding cassette transporter A1;clusterin;cystatin;presenilin;Lp-PLA2;Ghrelin;homocysteine, folate, Vitamin B12, leptin, adiponectin, resistin, visfatin, chemerin, pref-1, cartonectin, rbp-4, apelin, irisin;PAI-1, tPA, Aß40, Aß42, adipsin, IL-1ß;RL2 (O-GlcNAc); OGT; OGA; Total tau (Tau-5); p-Tau Ser396 (p-S396); p-Tau Ser404 (p-S404); p-Tau Thr212 (p-T212); p-Tau Thr231 (p-T231);BACE1, APOE4, 24-HyCL, CYP46A1, Sirt1, HMG-COAR, CML, INSIG-2 promoter, LPL, FFA, SREBP-1c, chemerin, RARRES2, sLRP1, LRP1; | — |
Countries
China
Contacts
Public ContactShaohua Wang
Affiliated ZhongDa Hospital of Southeast University
Outcome results
None listed